Invention Grant
- Patent Title: Plasma cytochrome C as a biomarker for mitochondrial toxicity during antiretroviral therapy
-
Application No.: US14725835Application Date: 2015-05-29
-
Publication No.: US10012648B2Publication Date: 2018-07-03
- Inventor: Elijah Paintsil , Allison Langs-Barlow
- Applicant: Yale University
- Applicant Address: US CT New Haven
- Assignee: Yale University
- Current Assignee: Yale University
- Current Assignee Address: US CT New Haven
- Agency: Saul Ewing Arnstein & Lehr LLP
- Agent Kathryn Doyle
- Main IPC: A61K39/21
- IPC: A61K39/21 ; G01N33/569

Abstract:
The present invention relates to the discovery that measurement of the level of cytochrome c (Cyt-C) in the plasma can be used as a diagnostic signature to predict antiretroviral therapy (ART) toxicity in human immunodeficiency virus (HIV) infected patients. Thus, in various embodiments described herein, the methods of the invention relate to methods of diagnosing a HIV patient with ART toxicity, methods of predicting a patient's risk of having or developing toxicity for ART, methods of assessing if a patient will benefit from a change in the treatment strategies by adjusting the dosage and/or changing the medication or even terminating of ART, and methods of predicting antiretroviral drugs propensity for causing mitochondrial toxicity. Furthermore, the invention encompasses a diagnostic kit for carrying out the aforementioned methods.
Public/Granted literature
- US20150346213A1 PLASMA CYTOCHROME C AS A BIOMARKER FOR MITOCHONDRIAL TOXICITY DURING ANTIRETROVIRAL THERAPY Public/Granted day:2015-12-03
Information query